Known as a sodium-glucose cotransporter-2, the blockbuster diabetes drug Invokana has been flying off the shelves, launching it to the top of the class of drugs also including Farxiga, Jardiance, Xigduo XR and Glyxambi. The drug presents a new and innovative way to treat the presence of glucose in the... Read more »

On Oct. 12, a Las Vegas jury was excused after a confidential resolution was reached in a civil trial regarding Actos, a diabetes drug. The medication is used in conjunction with diet and exercise to improve control of blood sugar in adults with type 2 diabetes mellitus. “We use the... Read more »

The U.S. Food and Drug Administration (FDA) has released a new drug safety communication regarding Invokana and Invokamet (canagliflozin). The safety announcement, which was released on September 10, 2015, adds a new warning to the drug’s label and updates the adverse reactions section with regard to the risk of bone... Read more »

Earlier this year, the U.S. Food and Drug Administration (FDA) published a safety communication that alerts consumers about an increased risk of diabetic ketoacidosis (DKA) with the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors, including Invokana, Invokamet, Farxiga, Jardiance and others. Diabetic ketoacidosis is a potentially life-threatening complication of diabetes... Read more »

Actos, a type 2 diabetes medication that has been linked in some studies to an increased risk of bladder cancer, is now suspected of raising the risk of other types of cancer as well. In addition to the much publicized Actos side effects to date, emerging research has determined that the... Read more »

A leading professional organization devoted to the care and treatment of diabetes patients has announced a conference convened to review ketoacidosis as one of a handful of possible SGLT2 inhibitor side effects.   The American Association of Clinical Endocrinologists (AACE) announced plans for the conference on June 29 after receiving questions... Read more »

The FDA issued a safety communication on May 15 warning of serious Invokana side effects involving ketoacidosis, a condition in which too much of certain kinds of acid (ketones) are found in the blood. The agency noted that several instances of the condition, resulting in hospitalization or emergency room visits,... Read more »

Even as popular diabetes drugs like Januvia and Actos continue to come under scrutiny, another diabetes drug has recently made headlines. Concerns over Onglyza heart failure have prompted a review by an FDA panel, which could lead to a label change for this drug and others like it. As “mortality”... Read more »

Cholesterol-lowering statins are among world’s most widely prescribed drugs, but concerns about Lipitor side effects, including the increased risk for Type 2 diabetes, has fueled a wave of litigation and further research on safer alternatives. As reported by the New York Times, a new study has found another type of... Read more »

U.S. District Judge Richard Gergel, who is currently overseeing Lipitor multidistrict litigation in South Carolina, has announced the first bellwether trial will begin in October 2015. Discovery in the Lipitor diabetes lawsuits is currently underway. A bellwether trial is used to help both sides gauge the jury reaction to evidence... Read more »